The Alpha‐1 <i>Pi</i> * <i> <scp>MZ</scp> </i> Genotype Is an Independent Risk Factor for Hepatocellular Carcinoma Development in Patients With <scp>ACLD</scp>
L Balcar(Medical University of Vienna), Mattias Mandorfer(Medical University of Vienna), Paul Thöne(Medical University of Vienna), R. Paternostro(Medical University of Vienna), Matthias Pinter(Medical University of Vienna), Georg Semmler(University of Southern Denmark), Benedikt Hofer(Austrian Academy of Sciences), Albert Friedrich Stättermayer(Medical University of Vienna), Mathias Jachs(Medical University of Vienna), Georg Kramer(Medical University of Vienna), B Scheiner(Medical University of Vienna), Christian Sebesta(Medical University of Vienna), Michael Trauner(Medical University of Vienna), Thomas Reiberger(Medical University of Vienna), Benedikt Simbrunner(Medical University of Vienna), Michael Schwarz(Medical University of Vienna), Lukas Hartl(Medical University of Vienna), Tina Jasmin Haunold(Medical University of Vienna), Nina Dominik(Medical University of Vienna)
Cited by 1
Related Papers
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
|Nature|2021|1.3k
Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFITY score
|Journal of Hepatology|2021|309
Cancer and liver cirrhosis: implications on prognosis and management
|ESMO Open|2016|287